[[9, 35, [[4, 547, "Table 2. Functionalized Pyrazole SAR"]]], [183, 196, [[322, 335, "O"]]], [245, 306, [[34, 160, "Compound"], [270, 302, "R2"], [423, 540, "IL-1\u03b2 IC5o (uM)a"], [612, 694, "cLogP cLogD"], [753, 820, "LLEb"]]], [336, 394, [[80, 114, "14"], [448, 516, "0.086"], [633, 675, "2.6 0.9"], [768, 807, "6.2"]]], [455, 514, [[79, 116, "15"], [454, 509, "2.57"], [632, 676, "2.4 0.5"], [768, 805, "5.1"]]], [597, 656, [[80, 114, "16"], [454, 507, "0.41"], [632, 676, "3.0 0.9"], [767, 810, "5.5"]]], [755, 820, [[80, 113, "17"], [405, 559, "0.063  0.042 (n=28)"], [632, 676, "2.0 0.4"], [768, 808, "6.7"]]], [916, 975, [[80, 114, "18"], [454, 509, "0.43"], [632, 676, "2.1 0.4"], [767, 810, "6.0"]]], [1075, 1132, [[80, 113, "19"], [461, 501, "6.2"], [636, 675, "1.8 0"], [767, 808, "5.2"]]], [1210, 1232, [[7, 847, "Inhibition of the NLRP3 inflammasome pathway was assessed by"]]], [1246, 1269, [[6, 848, "quantifying IL-1B release from LPS + nigericin stimulated hPBMCs"]]], [1282, 1304, [[7, 848, "n = 1 for all compounds except compound 17 which is reported as"]]], [1314, 1343, [[3, 851, "geometric mean  SD). LLE was calculated using the following"]]], [1350, 1378, [[6, 492, "equation: LLE = pICso IL-1\u03b2 - cLogD"]]]]